Single agent Rituximab4
|
Low tumor burden, poor performance status, slowly progressive
|
66% (initial)
40% (re-treatment)
|
mPFS: 21 months (initial)
mPFS: 18 months (re-treatment)
|
Rituximab + Chemo†5
|
First relapse, or late relapse
|
RR 1.28 favoring R-chemo
|
HR for mortality: 0.63
2y OS: 90%
|
Obinutuzumab+Bendamustine6 |
Rituximab
refractory |
57% |
mPFS: 25.8 months |
Anti-CD20 + lenalidomide7,9
|
Late or early relapse
|
65-77%
|
mPFS: 39 months
mTTP: 24 months
|
Lenalidomide9 |
Late or early relapse |
53% |
mTTP: 13.2 months |
Idelalisib10 |
After two prior therapies |
57% |
mPFS: 11 months |
Tazemetostat11 |
EZH2 mutation in first
relapse |
69% |
mPFS: 11 months |
Autologous HSCT12 |
Early treatment failure |
78% |
5y OS 73% |
Axicabtagene ciloleucel2 |
After two prior
therapies |
95% |
12 month DOR: 71.7% |
Pembrolizumab‡13
|
After failed
CAR-T |
27% |
n/a |
Lenalidomide +/-anti-CD20‡14
|
After failed CAR-T
|
63.6% (within 15 days of CAR-T infusion)
18.8% (15 days after CAR-T infusion)
|
n/a
|